<Disease><Name>CEROID LIPOFUSCINOSIS, NEURONAL, 2</Name><Synonym>CLN2; JANSKY-BIELSCHOWSKY DISEASE</Synonym><OMIM><Number>204500</Number><URL>http://omim.org/entry/204500</URL></OMIM><Orphanet><Number>228349</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=228349</URL></Orphanet><Protein><Number>Tripeptidyl-peptidase 1</Number><URL>http://www.uniprot.org/uniprot/O14773</URL></Protein><ExPASy><Number>3.4.14.9</Number><URL>http://enzyme.expasy.org/EC/3.4.14.9</URL></ExPASy><Gene>11p15.4</Gene><ICD>E75.4</ICD><Summary>rare;autosomal recessive;mutation in the TPP1 gene</Summary><Symptoms><symtomp><id>3424</id><symptom>abnormal movement</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2226</id><symptom>cerebral atrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>3816</id><symptom>developmental regression</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1946</id><symptom>dystonia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2160</id><symptom>EEG abnormalities [-]</symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>3709</id><symptom>epilepsy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2426</id><symptom>MRI, brain, white matter abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1900</id><symptom>myoclonus</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1739</id><symptom>optic atrophy</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1730</id><symptom>retinal or macular degeneration</symptom><category>EYES</category></symtomp><symtomp><id>2375</id><symptom>retinopathy</symptom><category>EYES</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>4056</id><symptom>seizures, tonic clonic</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2392</id><symptom>SEP (sensory evoked potentials), abnormal</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1874</id><symptom>speech development, delayed, abnormal</symptom><category>GENERAL TOPICS | NERVOUS SYSTEM</category></symtomp><symtomp><id>2393</id><symptom>VEP (visual evoked potentials), abnormal</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>3902</id><symptom>white matter changes, abnormalities</symptom><category>NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites /><Literatures><literature><id>4992</id><title>Management Strategies for CLN2 Disease</title><author>Williams RE,</author><journal>Pediatr Neurol</journal><year>2017</year><book /><volume>69</volume><number>0</number><pages>102-112</pages><co_aut>et al.</co_aut></literature><literature><id>4993</id><title>Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory di</title><author>Fietz M,</author><journal>Mol Genet Metab</journal><year>2016</year><book /><volume>119</volume><number>1</number><pages>160-167</pages><co_aut>et al.</co_aut></literature><literature><id>4995</id><title>CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis)</title><author>Kohlsch&#252;tter A,</author><journal>Pediatr Endocrinol Rev</journal><year>2016</year><book /><volume>13</volume><number>1</number><pages>682-688</pages><co_aut>Schulz A</co_aut></literature><literature><id>5001</id><title>Human NCL Neuropathology</title><author>Radke J,</author><journal>Biochim Biophys Acta</journal><year>2015</year><book /><volume>1852</volume><number>10</number><pages>2262-2266</pages><co_aut>Stenzel W, Goebel HH</co_aut></literature><literature><id>4994</id><title>Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease)</title><author>Katz ML,</author><journal>J Neurosci Res</journal><year>2014</year><book /><volume>92</volume><number>11</number><pages>1591-1598</pages><co_aut>et al.</co_aut></literature><literature><id>5002</id><title>Neuronal Ceroid-Lipofuscinoses</title><author>Mole SE,</author><journal>Source  GeneReviews&#174; [Internet]</journal><year>2013</year><book /><volume>0</volume><number>0</number><pages /><co_aut>Williams RE</co_aut></literature></Literatures></Disease>